Rossana Berardi

Summary

Country: Italy

Publications

  1. ncbi request reprint [Paraneoplastic syndromes: a review]
    R Berardi
    Clinica di Oncologia Medica, Azienda Ospedaliero, Universita Politecnica delle Marche, Ancona, Italia
    Clin Ter 156:281-8. 2005
  2. ncbi request reprint Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
    Tumori 91:463-6. 2005
  3. ncbi request reprint Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca 71, 60020 Ancona, Italy
    Cancer Treat Rev 32:333-47. 2006
  4. ncbi request reprint New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols
    Rossana Berardi
    Medical Oncology Unit of the Università Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
    JOP 6:118-21. 2005
  5. ncbi request reprint Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine
    R Berardi
    Medical Oncology Unit, University of Ancona, Ancona, Italy
    Oncology 65:198-203. 2003
  6. ncbi request reprint Mucocele-like tumour of the breast
    R Berardi
    Medical Oncology Unit, University of Ancona, Ancona, Italy
    J Exp Clin Cancer Res 22:329-32. 2003
  7. ncbi request reprint Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers
    R Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Ancona, Italy
    Lung Cancer 49:371-6. 2005
  8. doi request reprint Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Stefano Cascinu
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Cancer Chemother Pharmacol 68:37-43. 2011
  9. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
  10. doi request reprint Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy
    Expert Opin Pharmacother 10:2245-58. 2009

Detail Information

Publications68

  1. ncbi request reprint [Paraneoplastic syndromes: a review]
    R Berardi
    Clinica di Oncologia Medica, Azienda Ospedaliero, Universita Politecnica delle Marche, Ancona, Italia
    Clin Ter 156:281-8. 2005
    ..This review discusses all the main paraneoplastic syndromes, focusing mainly on their clinical aspect and reminding the most commonly associated cancers...
  2. ncbi request reprint Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
    Tumori 91:463-6. 2005
    ..The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer...
  3. ncbi request reprint Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca 71, 60020 Ancona, Italy
    Cancer Treat Rev 32:333-47. 2006
    ..In the second part we analysed the new molecular targets developing an hypothesis about the future therapeutics perspectives...
  4. ncbi request reprint New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols
    Rossana Berardi
    Medical Oncology Unit of the Università Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
    JOP 6:118-21. 2005
  5. ncbi request reprint Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine
    R Berardi
    Medical Oncology Unit, University of Ancona, Ancona, Italy
    Oncology 65:198-203. 2003
    ..The incidence of non-small cell lung cancer (NSCLC) is increasing among the elderly. We studied the toxicity and efficacy of a weekly schedule of gemcitabine and cisplatin in elderly patients with advanced NSCLC...
  6. ncbi request reprint Mucocele-like tumour of the breast
    R Berardi
    Medical Oncology Unit, University of Ancona, Ancona, Italy
    J Exp Clin Cancer Res 22:329-32. 2003
    ..Microscopic examination showed a ML tumour of the breast, with aspects of cribriform ductal hyperplasia...
  7. ncbi request reprint Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers
    R Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Ancona, Italy
    Lung Cancer 49:371-6. 2005
    ..Our results suggested that anemia could represent an important prognostic factor in resected NSCLC and correction of anemia in the perioperative setting does not reduce the risk of relapse...
  8. doi request reprint Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Stefano Cascinu
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Cancer Chemother Pharmacol 68:37-43. 2011
    ..With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C...
  9. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  10. doi request reprint Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy
    Expert Opin Pharmacother 10:2245-58. 2009
    ..This review discusses the role of neoadjuvant chemoradiotherapy regimens used in the standard combined modality treatment programs for rectal cancer and focuses on the ongoing research to improve these regimens...
  11. doi request reprint Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Int J Cancer 127:1941-7. 2010
    ..Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients...
  12. doi request reprint Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice
    Mirco Pistelli
    Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 97:275-9. 2011
    ..We retrospectively evaluated the efficacy of FOLFIRI as second-line treatment in advanced gastric cancer patients progressing after platinum-based chemotherapy...
  13. doi request reprint Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer
    Alessandro Brunelli
    Division of Thoracic Surgery, Ospedali Riuniti Ancona, Ancona, Italy
    J Thorac Cardiovasc Surg 146:385-90.e1-2. 2013
    ..The objective of this analysis was to develop a survival aggregate score (SAS), including objective and subjective patient-based parameters, and assess its prognostic role after major anatomic resection for non-small cell lung cancer...
  14. ncbi request reprint Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
    Mario Scartozzi
    Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    J Clin Oncol 25:3930-5. 2007
    ..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan...
  15. doi request reprint Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy
    Rossana Berardi
    Medical Oncology, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
    Dig Liver Dis 44:617-22. 2012
    ..NF-κB expression has been shown to be responsible for resistance to antineoplastic agents...
  16. doi request reprint Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Ancona, Italy
    Int J Radiat Oncol Biol Phys 75:1437-43. 2009
    ..To determine the importance of downstaging of locally advanced rectal cancer after neoadjuvant treatment...
  17. ncbi request reprint COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Am J Clin Oncol 30:526-30. 2007
    ..We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer...
  18. doi request reprint The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Dig Liver Dis 43:194-8. 2011
    ..The benefit of preoperative chemotherapy in patients with initially resectable liver metastases from colorectal cancer is still a matter of debate...
  19. doi request reprint Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi G Salesi di Ancona, Medical Oncology Unit, 60020 Ancona, Italy
    Expert Opin Pharmacother 10:2467-78. 2009
    ..The present review analyzes the new molecular targets that could be involved in predicting response and prognosis...
  20. doi request reprint Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 6020 Ancona, Italy
    Lung Cancer 68:433-7. 2010
    ....
  21. pmc The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    Oncologist 16:53-60. 2011
    ..Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients...
  22. ncbi request reprint Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?
    Matteo Santoni
    Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Curr Cancer Drug Targets 13:313-25. 2013
    ....
  23. doi request reprint Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients
    Mario Scartozzi
    Clinica di Oncologia, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Dig Liver Dis 44:74-9. 2012
    ..Retrospective analyses suggested that a pharmacogenetic approach may allow a tailored selection of chemotherapy for metastatic colorectal cancer...
  24. ncbi request reprint Maspin expression is a favorable prognostic factor in non-small cell lung cancer
    Rossana Berardi
    Department of Medical Oncology, Section of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi G Salesi, Ancona, Italy
    Anal Quant Cytol Histol 34:72-8. 2012
    ..To evaluate prognostic impact of maspin expression in patients with resected non-small cell lung cancer (NSCLC)...
  25. ncbi request reprint Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies
    Mario Scartozzi
    Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
    J Clin Oncol 22:4772-8. 2004
    ....
  26. doi request reprint Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review
    Rossana Berardi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
    Crit Rev Oncol Hematol 69:223-36. 2009
    ..We extensively reviewed the published scientific literature on this topic in order to investigate the clinical and genetic profiling underlying lung cancer in women and to use this information as a tool for medical therapy...
  27. doi request reprint Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 71, Ancona, 60020, Italy
    Curr Oncol Rep 12:175-85. 2010
    ..Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients...
  28. ncbi request reprint Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona and Istituto di Anatomia Patologica, Universita Politecnica delle Marche, Ancona, Italy
    Anal Quant Cytol Histol 28:61-8. 2006
    ..Moreover, the biological selection of colorectal tumors more likely to benefit from this treatment approach is still to be defined...
  29. ncbi request reprint Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
    Mario Scartozzi
    AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
    Curr Opin Mol Ther 12:361-71. 2010
    ..Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice...
  30. ncbi request reprint Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti e Università Politecnica delle Marche, Ancona, Italy
    Lung Cancer 53:103-9. 2006
    ..031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies...
  31. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
    ..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
  32. doi request reprint State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review
    Rossana Berardi
    Medical Oncology, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi, Ancona, Italy Electronic address
    Crit Rev Oncol Hematol 88:75-86. 2013
    ....
  33. ncbi request reprint Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice
    Mirco Pistelli
    Department of Medical Oncology, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Anticancer Res 33:2737-42. 2013
    ..We aimed to verify whether clinical and/or pathological features may help us identify triple-negative breast cancer with a different outcome...
  34. pmc Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi, Ancona, Italy
    Onco Targets Ther 6:563-76. 2013
    ..This review is an overview of ongoing Phase I, II, and III trials of novel small molecule epidermal growth factor receptor inhibitors and combinations in non-small cell lung cancer patients...
  35. ncbi request reprint Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Tumour Biol 25:106-10. 2004
    ..Some of the mechanisms inducing E-cadherin downregulation, like hypermethylation, may be potentially reversible, and they deserve further investigation as the target of novel therapeutic strategies...
  36. doi request reprint Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Cancer Treat Rev 35:451-62. 2009
    ..This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research...
  37. doi request reprint 5-Fluorouracil pharmacogenomics: still rocking after all these years?
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Pharmacogenomics 12:251-65. 2011
    ..In this article, we will focus on the often contradictory results of these studies...
  38. ncbi request reprint Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 92:384-8. 2006
    ..We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy...
  39. doi request reprint Pancreatic cancer: progress in cancer therapy
    Chiara Pierantoni
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Crit Rev Oncol Hematol 67:27-38. 2008
    ..New treatment strategies and a more careful evaluation of innovative therapies are clearly needed for this disease. In this review we will focus on treatment strategies both in resectable and advanced pancreatic cancer...
  40. pmc Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    J Exp Clin Cancer Res 29:164. 2010
    ..In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome...
  41. doi request reprint Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options
    Luca Faloppi
    Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
    Cancer Treat Rev 37:169-77. 2011
    ..Only recently the molecular targeted drug, Sorafenib, has been introduced among the therapeutic options for these patients...
  42. ncbi request reprint Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors
    Rossana Berardi
    Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Anal Quant Cytol Histol 33:196-204. 2011
    ..To verify whether epidermal growth factor receptor (EGFR) status could be considered a prognostic factor and assessment of it an effective tool for planning therapy in patients with non-small cell lung cancer (NSCLC)...
  43. ncbi request reprint State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Ancona, Italy
    Discov Med 11:144-53. 2011
    ..The efficacy profile seems to be promising. However, further studies are needed to define the exact role of IGF-1R inhibitors in clinical practice...
  44. doi request reprint Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer
    Cecilia Pompili
    Division of Thoracic Surgery, Ospedali Riuniti Ancona, Ancona, Italy
    Eur J Cardiothorac Surg 43:905-10. 2013
    ..The objective of this study was to assess the prognostic role of preoperative quality of life (QoL) in patients operated on for early-stage non-small-cell lung cancer (NSCLC)...
  45. doi request reprint Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer
    Alessandro Brunelli
    Ospedali Riuniti Ancona, Ancona, Italy
    Ann Thorac Surg 93:1796-800. 2012
    ..This investigation evaluated whether the performance at a preoperative symptom-limited stair-climbing test was a prognostic factor in resected pathologic stage I non-small cell lung cancer (NSCLC)...
  46. ncbi request reprint Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy
    Filippo Grillo-Ruggieri
    Dipartimento di Oncologia e Radioterapia Generale, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Dis Colon Rectum 50:1594-603. 2007
    ..The aim of this study was to evaluate downstaging as primary end point, and progression-free survival and overall survival as secondary end points, in rectal adenocarcinoma patients treated with preoperative chemoradiation...
  47. ncbi request reprint Chemotherapy for advanced gastric cancer: across the years for a standard of care
    Mario Scartozzi
    Universita Politecnica delle Marche, Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
    Expert Opin Pharmacother 8:797-808. 2007
    ..The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy...
  48. ncbi request reprint Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice
    Mario Scartozzi
    Azienda Ospedaliera Ospedali Riuniti Universita, Clinica di Oncologia Medica, Politecnica delle Marche, Via Conca 60020, Ancona, Italy
    Expert Opin Ther Targets 10:281-7. 2006
    ..Moreover, the biological selection of colorectal tumours most likely to benefit from this treatment approach is still to be defined...
  49. ncbi request reprint Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Via Bonconte da Montefeltro, 61029, Urbino, Italy
    J Clin Oncol 23:2339-45. 2005
    ..The prognostic role of IL-1B/IL-1RN genotypes was investigated in patients with relapsed and metastatic gastric cancer treated with palliative chemotherapy...
  50. ncbi request reprint [Non-small cell lung carcinoma: pathology, biology and prognosis]
    Federica Freddari
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona
    Suppl Tumori 3:S3-4. 2004
  51. doi request reprint Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma
    Matteo Santoni
    Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Via Conca 71, 60126, Ancona, Italy
    Cancer Immunol Immunother 62:1757-68. 2013
    ....
  52. pmc Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
    Core Evid 5:61-76. 2010
    ..The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice...
  53. ncbi request reprint Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature
    Rossana Berardi
    Medical Oncology Department, University of Ancona, Azienda Ospedaliera Umberto I, Ancona, Italy
    Suppl Tumori 2:S45-7. 2003
    ..The aim of the present review is to summarize the results of previously performed randomized trials to evaluate the effects of adjuvant therapy in gastric cancer...
  54. ncbi request reprint [The DUR studies: colon cancer adjuvants]
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona
    Suppl Tumori 3:S88. 2004
  55. ncbi request reprint Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
    Mario Scartozzi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, Ancona, Italy
    Cancer Treat Rev 30:451-9. 2004
    ..e., thymidilate synthase that is targeted by 5FU) or to a new class of antineoplastic molecules (i.e., c-erb B-2 targeted by trastuzumab, COX-2 by NSAIDs, matrix metalloproteinases, EGFR and VEGFR by specific inhibitors)...
  56. doi request reprint Resected biliary tract cancers: a novel clinical-pathological score correlates with global outcome
    Rossana Berardi
    Medical Oncology, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi, Ancona, Italy
    Dig Liver Dis 45:70-4. 2013
    ..Biliary tract cancer presents a poor prognosis...
  57. ncbi request reprint Gastric cancer treatment: a systematic review
    Rossana Berardi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, 60020 Ancona, Italy
    Oncol Rep 11:911-6. 2004
    ..This review will focus on the several treatment modalities available for gastric cancer patients: surgery, adjuvant, neoadjuvant and palliative chemotherapy as well as new target agents...
  58. pmc Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
    Matteo Santoni
    Clinica di Oncologia Medica, AOU Ospedali Riuniti, Universita Politecnica delle Marche, Via Tronto 10 A, 60100 Ancona, Italy
    J Neurooncol 113:397-401. 2013
    ..This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile...
  59. pmc Progress of molecular targeted therapies for advanced renal cell carcinoma
    Alessandro Conti
    Department of Clinical and Specialist Sciences, Urology, Polytechnic University of the Marche Region, AOU Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Biomed Res Int 2013:419176. 2013
    ..Here we illustrate the main steps of tumor angiogenesis process, defining the pertinent therapeutic targets and the efficacy and toxicity profiles of these new promising agents. ..
  60. ncbi request reprint Essential role of Gli proteins in glioblastoma multiforme
    Matteo Santoni
    Clinica di Oncologia Medica, AOU Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    Curr Protein Pept Sci 14:133-40. 2013
    ..This review will summarize the role of Gli proteins in GBM tumorigenesis and their potential impact on GBM therapy and treatment resistance...
  61. pmc Role of maspin in cancer
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca, Ancona, 71 60126, Italy
    Clin Transl Med 2:8. 2013
    ..Further studies in these directions are necessary to better define the therapeutic implication of maspin...
  62. ncbi request reprint Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target
    Mario Scartozzi
    Clinic of Medical Oncology, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona Italy
    Anal Quant Cytol Histol 31:417-23. 2009
    ..To clarify the role of epidermal growth factor receptor (EGFR) promoter methylation in primary colorectal cancers and corresponding metastases and its relationship to EGFR expression...
  63. ncbi request reprint Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity
    Matteo Santoni
    Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Recent Pat Antiinfect Drug Discov 7:104-10. 2012
    ....
  64. ncbi request reprint Desmoplastic small round cell tumour: a description of two cases and review of the literature
    Paolo Lippe
    Medical Oncology Unit, Fano, Italy
    Oncology 64:14-7. 2003
    ..The authors report two additional cases of DSRCT and review the available medical literature...
  65. ncbi request reprint Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
    Allan Lipton
    Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Clin Oncol 25:4431-7. 2007
    ..In this study, we evaluated the efficacy and safety of five dosing regimens of denosumab in patients with breast cancer-related bone metastases not previously treated with intravenous bisphosphonates (IV BPs)...
  66. ncbi request reprint Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer
    Valentina Guarneri
    Department of Oncology and Hematology, Modena University Hospital, Via del Pozzo 71, 41100 Modena, Italy
    Breast Cancer Res Treat 110:127-34. 2008
    ..Secondary aims: to evaluate EGFR, (p)-EGFR, Ki67, apoptotic index (TUNEL test) and VEGFR2 expression from baseline to surgery, percentage of pathologic complete response (pCR), and toxicity...
  67. ncbi request reprint A cost-benefit analysis of chemotherapy for gastric cancer
    Eva Galizia
    Univeritaria Ospedali Riuniti Umberto I, Salesi, Lancisi di Ancona, Italy
    Expert Opin Pharmacother 5:2109-14. 2004
    ..The aim of this paper is to review the results of the main studies regarding the relationship between the cost of chemotherapy and its effectiveness in advanced gastric and gastrointestinal cancer patients...
  68. ncbi request reprint Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel
    Rossana Berardi
    Am J Med 115:415-7. 2003